Summary
Severe coronavirus disease of 2019 (COVID-19) positively correlates with age (Centers for Disease Control), develops after progression of infection from the upper airway to the lower respiratory tract (LRT), and can worsen into acute respiratory distress syndrome (ARDS) (Shi et al., 2020). Why children seem to be less likely to develop severe disease remains unclear. As the nasal mucosa (NM) is the first site of contact and defense for respiratory pathogens such as SARS-CoV-2 before dissemination to the LRT (Casadei and Salinas, 2019), we hypothesized that differences in this tissue across the age range may help explain the disparity in COVID-19 severity. To this end, we profiled NM samples across the lifespan in health and disease. We find that global transcriptomic changes including the expression of SARS-CoV-2 and coronavirus-associated receptors and factors are not correlated with age or the novel virus type, since pediatric NM cells mount similar antiviral response to both SARS-CoV-2 or Influenza B. Rather, we find immune cell residency in NM decreases dramatically with age especially cells of the innate immune system. This includes a resident-memory-like T cell subset with antiviral properties. These observations give plausible biological explanation to the observed clinical differences in disease spectrum and provide a foundation for future experimental studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. E.G. holds the Roberta D. Harding & William F. Bradley, Jr. Endowed Chair in Genomic Research and T.P. holds the Dee Lyons/Missouri Endowed Chair in Pediatric Genomic Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study subjects were enrolled at Childrens Mercy either using salvage sample collection protocol or using prospective cohort study protocols. Specifically, the NM cohort of COVID-19 negative individuals included patients aged 0 to 18 years tested for COVID-19 as a part of their standard of care procedure, and healthcare workers screened for COVID-19, these samples were collected using a salvage sample protocol (IRB # STUDY00001258). Similarly, patients undergoing multiplex testing for respiratory viruses were regularly screened and all children positive for Influenza B were selected for the NM cohort of Influenza B positive children these samples were collected using salvage sample protocol (IRB # STUDY00001193). For both groups, subjects were deidentified and samples stored at 4˚C were collected within 12 hours of test results. For COVID-19 positive children, families were enrolled in the CODIEFY study approved by the Institute Review Board (IRB) at Childrens Mercy (IRB # STUDY00001317). Parents or legally appointed representatives of COVID-19 positive children were approached for enrollment and verbal consent within 24-48 hours of their test results, and children aged 7 years and above have given verbal informed assent. Respiratory and blood specimens were collected and transported by a home-health care nurse following standard precautions within the next 24-48 hours. Samples were processed for nasal cell isolation and PBMC isolation within 2 - 4 hours of collection. Finally, the PBMC cohort of COVID-19 negative children were enrolled in the Genomics Answers for Kids Program approved by the Institute Review Board (IRB) at Childrens Mercy (IRB # 11120514). Participants have given written informed consent to collect pertinent medical information and family history from their medical record and give a blood sample. Blood draws for the study were paired with clinical draws when possible.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw and processed data from all pooled samples is available via the Gene Expression Omnibus (accession number: GSE162864). Raw data from individual samples are available upon request through EGA and dbGAP upon approval from the Data Access Committee. Fully processed data are available for exploration through the UCSC cell browser (lifespan-nasal-atlas.cells.ucsc.edu)
